121 related articles for article (PubMed ID: 1738928)
1. The ability of pretransplant test-dose pharmacokinetic profiles to reduce early adverse events after renal transplantation.
Kahan BD; Welsh M; Rutzky L; Lewis R; Knight R; Katz S; Napoli K; Grevel J; Van Buren CT
Transplantation; 1992 Feb; 53(2):345-51. PubMed ID: 1738928
[TBL] [Abstract][Full Text] [Related]
2. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.
Canadian Neoral Renal Transplantation Study Group
Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295
[TBL] [Abstract][Full Text] [Related]
3. Pretransplant test-dose pharmacokinetic profiles: cyclosporine microemulsion versus corn oil-based soft gel capsule formulation.
Chueh SC; Kahan BD
J Am Soc Nephrol; 1998 Feb; 9(2):297-304. PubMed ID: 9527407
[TBL] [Abstract][Full Text] [Related]
4. The impact of steady-state cyclosporine concentrations on renal allograft outcome.
Dunn J; Grevel J; Napoli K; Lewis RM; Van Buren CT; Kahan BD
Transplantation; 1990 Jan; 49(1):30-4. PubMed ID: 2301023
[TBL] [Abstract][Full Text] [Related]
5. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
Gonwa TA; Hricik DE; Brinker K; Grinyo JM; Schena FP;
Transplantation; 2002 Dec; 74(11):1560-7. PubMed ID: 12490789
[TBL] [Abstract][Full Text] [Related]
6. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation.
Mahalati K; Belitsky P; Sketris I; West K; Panek R
Transplantation; 1999 Jul; 68(1):55-62. PubMed ID: 10428267
[TBL] [Abstract][Full Text] [Related]
7. Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection.
Kahan BD; Welsh M; Schoenberg L; Rutzky LP; Katz SM; Urbauer DL; Van Buren CT
Transplantation; 1996 Sep; 62(5):599-606. PubMed ID: 8830822
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
Thervet E; Pfeffer P; Scolari MP; Toselli L; Pallardó LM; Chadban S; Pilmore H; Connolly J; Buchler M; Schena FP; Carreño CA; Dandavino R; Cole E
Transplantation; 2003 Sep; 76(6):903-8. PubMed ID: 14508352
[TBL] [Abstract][Full Text] [Related]
9. The adverse impact of high cyclosporine. Clearance rates on the incidences of acute rejection and graft loss.
Lindholm A; Welsh M; Rutzky L; Kahan BD
Transplantation; 1993 May; 55(5):985-93. PubMed ID: 8497912
[TBL] [Abstract][Full Text] [Related]
10. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group.
Keown P; Landsberg D; Halloran P; Shoker A; Rush D; Jeffery J; Russell D; Stiller C; Muirhead N; Cole E; Paul L; Zaltzman J; Loertscher R; Daloze P; Dandavino R; Boucher A; Handa P; Lawen J; Belitsky P; Parfrey P
Transplantation; 1996 Dec; 62(12):1744-52. PubMed ID: 8990355
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of pretransplantation cyclosporine pharmacokinetic studies on initial post-transplantation dosing in pediatric kidney allograft recipients.
Seikku P; Hoppu K; Jalanko H; Holmberg C
Pediatr Transplant; 2003 Apr; 7(2):102-10. PubMed ID: 12654050
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic strategies for cyclosporin therapy in organ transplantation.
Kahan BD; Welsh M; Knight R; Katz S; Lewis R; Grevel J; Van Buren CT
J Autoimmun; 1992 Apr; 5 Suppl A():333-41. PubMed ID: 1503629
[TBL] [Abstract][Full Text] [Related]
13. Study of cyclosporine level at 2 hours after administration in preoperative kidney transplant recipients for prediction of postoperative optimal cyclosporine dose.
Sukhavasharin N; Praditpornsilpa K; Avihingsanon Y; Kuoatawintu P; O-Charoen R; Kansanabuch T; Tungsanga K; Eiam-Ong S
J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S15-20. PubMed ID: 17044449
[TBL] [Abstract][Full Text] [Related]
14. Improved immunosuppression for heart transplant patients using intravenous doses of cyclosporine.
Macris MP; Frazier OH; Van Buren CT; Lammermeier DE; Kahan BD
Transplantation; 1989 Feb; 47(2):311-4. PubMed ID: 2493177
[TBL] [Abstract][Full Text] [Related]
15. Correlation between pretransplantation test dose cyclosporine pharmacokinetic profiles and posttransplantation sirolimus blood levels in renal transplant recipients.
Kaplan B; Meier-Kriesche HU; Napoli KL; Kahan BD
Ther Drug Monit; 1999 Feb; 21(1):44-9. PubMed ID: 10051053
[TBL] [Abstract][Full Text] [Related]
16. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation].
Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L
Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420
[TBL] [Abstract][Full Text] [Related]
17. Specific monoclonal radioimmunoassay and fluorescence polarization immunoassay for trough concentration and area-under-the-curve monitoring of cyclosporine in renal transplantation.
Lindholm A; Napoli K; Rutzky L; Kahan BD
Ther Drug Monit; 1992 Aug; 14(4):292-300. PubMed ID: 1519303
[TBL] [Abstract][Full Text] [Related]
18. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin.
Hausen B; Gummert J; Berry GJ; Christians U; Serkova N; Ikonen T; Hook L; Legay F; Schuler W; Schreier MH; Morris RE
Transplantation; 2000 Feb; 69(4):488-96. PubMed ID: 10708100
[TBL] [Abstract][Full Text] [Related]
19. Clinical success of Neoral absorption profile.
Uchida K; Tominaga Y; Haba T; Katayama A; Matsuoka S; Goto N; Ueki T; Kimata T; Takeda A; Morozumi K; Takagi H; Nakao A
Transplant Proc; 2004 Mar; 36(2 Suppl):461S-464S. PubMed ID: 15041388
[TBL] [Abstract][Full Text] [Related]
20. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?
Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G
Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
